Targeting angiogenesis with antibodies for the treatment of cancer

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Targeting tumor angiogenesis, the process of new blood vessel formation, is a long-standing cancer treatment strategy.
• Therapeutic antibodies, particularly monoclonal antibodies (mAbs), have emerged as promising agents for cancer therapy.
• Avastin (bevacizumab), a mAb targeting vascular endothelial growth factor (VEGF), has shown efficacy in treating colorectal, lung, and breast cancers.

Purpose of the Study:

• To explore novel therapeutic targets in angiogenesis beyond established factors like VEGF.
• To investigate the roles of angiomotin and placenta growth factor (PlGF) in tumor angiogenesis.
• To advance the development of new anti-cancer therapies by targeting these novel factors.

Main Methods:

• Investigating monoclonal antibodies (mAbs) and low-molecular-weight substances targeting angiogenesis.
• Focusing research on angiomotin, a receptor for the anti-angiogenic factor angiostatin.
• Researching the pro-angiogenic factor placenta growth factor (PlGF).

Main Results:

• Monoclonal antibodies targeting VEGF, like Avastin, demonstrate clinical benefit in several cancer types.
• Angiogenesis is a complex process involving both pro- and anti-angiogenic factors, necessitating diverse therapeutic strategies.
• Ongoing research targets various pro-angiogenic factors, receptors, and antigens on newly formed blood vessels.

Conclusions:

• Targeting angiogenesis remains a critical approach in cancer therapy.
• Development of therapeutic antibodies and exploration of novel targets like angiomotin and PlGF hold significant potential for future cancer treatments.
• A multifaceted approach targeting different aspects of angiogenesis is crucial for effective cancer intervention.